Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: ELA Medical

This article was originally published in The Gray Sheet

Executive Summary

ELA Medical: U.S. clinical trials commence for the Defender II dual-chamber pacer/implantable cardioverter defibrillator following FDA clearance of an investigational device exemption covering 50 patients at 10 centers. Using ELA's Parad algorithm, the Defender II takes readings from the atrium and the ventricle for enhanced arrhythmia detection to reduce the incidence of inappropriate therapies, the firm maintains...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel